Resistin mediates the hepatic stellate cell phenotype

Area of Science:

• Hepatology
• Endocrinology
• Immunology

Background:

• Liver fibrosis is a significant health concern.
• Resistin, an adipokine, has been implicated in various inflammatory conditions.
• Its specific role in liver fibrosis remains to be fully elucidated.

Purpose of the Study:

• To investigate the role of resistin in the pathogenesis of liver fibrosis.
• To determine the direct and indirect effects of resistin on hepatic stellate cells (HSCs) and Kupffer cells (KCs).

Main Methods:

• In vivo study: Bile duct ligation (BDL) in Sprague Dawley rats to induce liver fibrosis.
• In vitro study: Primary rat HSCs and KCs treated with recombinant resistin.
• Analysis of gene and protein expression (collagen I, TGF-β1, α-SMA, TIMP-1, CTGF, TNF-α, IL-1, IL-6, IL-8, MCP-1), MAPK/p38 signaling, HSC proliferation, migration, and apoptosis.

Main Results:

• Resistin expression increased in epididymal fat and serum following BDL.
• Resistin treatment enhanced pro-fibrogenic and pro-inflammatory gene/protein expression in HSCs (IL-6, MCP-1).
• Resistin activated p38 MAPK in HSCs, promoted HSC proliferation and migration, and inhibited apoptosis, partly via IL-6 and MCP-1. Resistin also induced TGF-β1 from KCs, further enhancing HSC collagen I expression.

Conclusions:

• Resistin directly and indirectly promotes liver fibrosis.
• Resistin modulates HSC behavior towards a pro-fibrogenic phenotype through inflammatory and signaling pathways.
• Resistin represents a potential therapeutic target for liver fibrosis.